Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
As of today, Eli Lilly(LLY) shares are valued at $1,187.04. The company's market cap stands at 1.12T, with a P/E ratio of 42.09 and a dividend yield of 0.55%.
During the trading session on 2026-07-23, Eli Lilly(LLY) shares reached a daily high of $1,189.59 and a low of $1,142.01. At a current price of $1,187.04, the stock is +3.9% higher than the low and still -0.2% under the high.
Trading volume for Eli Lilly(LLY) stock has reached 974.75K, versus its average volume of 2.32M.
The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.
The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.
LLY News
Biotech and Pharma Lilly Stock Is Rising on Plan to Seek Approval for Newest Weight-Loss Drug in 2027 In this article SPX Eli Lilly’s weight loss drugs have cat...
Pharmaceutical giant Eli Lilly (LLY) says it is targeting the first quarter of 2027 for approval of its next-generation weight-loss drug. Claim 55% Off TipRanks...
The race to treat obesity and diabetes is shifting again after Eli Lilly pushed back approval plans for its next-generation obesity drug, retatrutide, to Q1 202...
Analyst ratings
81%
of 31 ratingsMore LLY News
Key Points Eli Lilly is going to buy a psychedelic drug biotech called AtaiBeckley. It'll be getting a handful of mid-stage clinical programs for behavioral h...
The studies demonstrated significant weight reduction in adult patients managing obesity alongside severe complications, including type 2 diabetes and establish...
Eli Lilly (LLY) on Thursday announced plans to seek FDA approval for its next-gen weight-loss therapy, retatrutide, early next year after the triple hormone rec...
Eli Lilly (LLY) announced topline results from TRIUMPH-2 and TRIUMPH-3, two Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1...
Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide. Scott Olson / Getty Images Eli Lilly LLY -1.05 %decrease; d...
Eli Lilly on Thursday said it will file for approval of its next-generation obesity drug in the first quarter of 2027, as the treatment succeeds in two more lat...
Eli Lilly launched its FDA approved Alzheimer's drug Kisunla, adding a new treatment option to its neuroscience portfolio. The company is preparing prominent p...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.